Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
Section snippets
Somatostatin Receptor–Based Radionuclide Therapy
Gastroenteropancreatic neuroendocrine tumors (GEPNETs), which comprise functioning and nonfunctioning endocrine pancreatic tumors and carcinoids, are usually slow-growing. When metastasized, treatment with somatostatin analogues results in reduced hormonal overproduction and symptomatic relief in most cases. Treatment with somatostatin analogues is however seldom successful in terms of tumor size reduction.2, 3, 4
A new treatment modality for patients with inoperable or metastasized endocrine
Conclusions
Treatment with radiolabeled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all 111In, 90Y, or 177Lu-labeled somatostatin analogues that have been used for PRRT. The results that were obtained with [90Y-DOTA0, Tyr3]octreotide and [177Lu-DOTA0, Tyr3]octreotate are very encouraging in terms of tumor regression. Also, if kidney protective agents are used, the side effects of
References (68)
- et al.
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Am J Gastroenterol
(2000) - et al.
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The Rotterdam experience
Semin Nucl Med
(2002) - et al.
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
Semin Nucl Med
(2002) - et al.
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
Ann Oncol
(2001) - et al.
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors
Semin Nucl Med
(2006) - et al.
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: The experience of the European Institute of Oncology group
Semin Nucl Med
(2002) - et al.
111In- and 90Y-DOTA-Lanreotide: Results and implications of the Mauritius trial
Semin Nucl Med
(2002) - et al.
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
Ann Oncol
(1997) - et al.
Epidemiology and survival in patients with carcinoid disease in the NetherlandsAn epidemiological study with 2391 patients
Ann Oncol
(2001) - et al.
Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: A 10-year experience evaluating predictors of survival
Surgery
(2007)
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
Semin Nucl Med
Localization of endocrine related tumors with radioiodinated analogue of somatostatin
Lancet
Gastroenteropancreatic endocrine tumours: Effect of Sandostatin on tumour growthThe German Sandostatin Study Group
Digestion
Long-term management of the carcinoid syndromeTreatment with octreotide alone and in combination with alpha-interferon
Acta Oncol
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs
J Nucl Med
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC
J Nucl Med
Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?
Eur J Nucl Med Mol Imaging
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study
Eur J Nucl Med Mol Imaging
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: Toxicity, efficacy, and survival
J Clin Oncol
Yttrium-90 DOTATOC: First clinical results
Eur J Nucl Med
90Y-DOTA-D-Phe1–Tyr3-octreotide in therapy of neuroendocrine malignancies
Biopolymers
Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0, Tyr3]octreotide in patients with somatostatin receptor positive tumours (abstract)
Eur J Nucl Med Mol Imaging
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors
J Nucl Med
Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy
Cancer Res
High radiotherapeutic efficacy of [Lu-177]-DOTA-Y(3)-octreotate in a rat tumor model (abstract)
J Nucl Med
Affinity profiles for human somatostatin receptor SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use
Eur J Nucl Med
[177Lu-DOTA0Tyr3]octreotate: Comparison with [111In-DTPA0]octreotide in patients
Eur J Nucl Med
Comparison of [(177)Lu-DOTA(0), Tyr(3)]octreotate and [(177)Lu-DOTA(0), Tyr(3)]octreotide: Which peptide is preferable for PRRT?
Eur J Nucl Med Mol Imaging
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate
Eur J Nucl Med Mol Imaging
Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate in patients with gastro-entero-pancreatic (GEP) tumors
J Clin Oncol
Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate
Eur J Nucl Med Mol Imaging
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0, Tyr3]octreotate
J Clin Oncol
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
Cancer Biother Radiopharm
Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga
Der Onkologe
Cited by (129)
A clinical perspective on ectopic Cushing's syndrome
2023, Trends in Endocrinology and MetabolismTherapy of NET with radiolabeled SST analogs
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4Theranostics and radiopharmaceuticals in cancer treatment
2021, Handbook on Nanobiomaterials for Therapeutics and Diagnostic ApplicationsMetallic radionuclides for diagnostic imaging and cancer radiotherapy: The development of theragnostic matched pairs and targeted alpha therapy
2021, Advances in Inorganic ChemistryPractical aspects of peptide receptor radionuclide therapy with somatostatin analogs in 2019
2019, Medecine NucleaireOutcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
2023, Journal of Gastrointestinal Oncology